Cargando…
Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2014
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288573/ http://dx.doi.org/10.1186/2051-1426-2-S3-P179 |
| _version_ | 1782351991875305472 |
|---|---|
| author | Brahmer, Julie Balmanoukian, Ani Goldberg, Sarah Ou, Sai-Hong Blake-Haskins, Andrew Karakunnel, Joyson Stockman, Paul Rizvi, Naiyer Antonia, Scott |
| author_facet | Brahmer, Julie Balmanoukian, Ani Goldberg, Sarah Ou, Sai-Hong Blake-Haskins, Andrew Karakunnel, Joyson Stockman, Paul Rizvi, Naiyer Antonia, Scott |
| author_sort | Brahmer, Julie |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4288573 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2014 |
| publisher | BioMed Central |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-42885732015-01-15 Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) Brahmer, Julie Balmanoukian, Ani Goldberg, Sarah Ou, Sai-Hong Blake-Haskins, Andrew Karakunnel, Joyson Stockman, Paul Rizvi, Naiyer Antonia, Scott J Immunother Cancer Poster Presentation BioMed Central 2014-11-06 /pmc/articles/PMC4288573/ http://dx.doi.org/10.1186/2051-1426-2-S3-P179 Text en Copyright © 2014 Brahmer et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| spellingShingle | Poster Presentation Brahmer, Julie Balmanoukian, Ani Goldberg, Sarah Ou, Sai-Hong Blake-Haskins, Andrew Karakunnel, Joyson Stockman, Paul Rizvi, Naiyer Antonia, Scott Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) |
| title | Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) |
| title_full | Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) |
| title_fullStr | Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) |
| title_full_unstemmed | Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) |
| title_short | Development of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC) |
| title_sort | development of medi4736, an anti-programmed cell death ligand 1 (pd-l1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (nsclc) |
| topic | Poster Presentation |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288573/ http://dx.doi.org/10.1186/2051-1426-2-S3-P179 |
| work_keys_str_mv | AT brahmerjulie developmentofmedi4736anantiprogrammedcelldeathligand1pdl1antibodyasmonotherapyorincombinationwithothertherapiesinthetreatmentofnonsmallcelllungcancernsclc AT balmanoukianani developmentofmedi4736anantiprogrammedcelldeathligand1pdl1antibodyasmonotherapyorincombinationwithothertherapiesinthetreatmentofnonsmallcelllungcancernsclc AT goldbergsarah developmentofmedi4736anantiprogrammedcelldeathligand1pdl1antibodyasmonotherapyorincombinationwithothertherapiesinthetreatmentofnonsmallcelllungcancernsclc AT ousaihong developmentofmedi4736anantiprogrammedcelldeathligand1pdl1antibodyasmonotherapyorincombinationwithothertherapiesinthetreatmentofnonsmallcelllungcancernsclc AT blakehaskinsandrew developmentofmedi4736anantiprogrammedcelldeathligand1pdl1antibodyasmonotherapyorincombinationwithothertherapiesinthetreatmentofnonsmallcelllungcancernsclc AT karakunneljoyson developmentofmedi4736anantiprogrammedcelldeathligand1pdl1antibodyasmonotherapyorincombinationwithothertherapiesinthetreatmentofnonsmallcelllungcancernsclc AT stockmanpaul developmentofmedi4736anantiprogrammedcelldeathligand1pdl1antibodyasmonotherapyorincombinationwithothertherapiesinthetreatmentofnonsmallcelllungcancernsclc AT rizvinaiyer developmentofmedi4736anantiprogrammedcelldeathligand1pdl1antibodyasmonotherapyorincombinationwithothertherapiesinthetreatmentofnonsmallcelllungcancernsclc AT antoniascott developmentofmedi4736anantiprogrammedcelldeathligand1pdl1antibodyasmonotherapyorincombinationwithothertherapiesinthetreatmentofnonsmallcelllungcancernsclc |